The JointHealth™ Report Card and Arthritis Medications Guide issue
While there are no cures for arthritis, scientific advances and improved treatments, along with a better understanding of combination medication therapy, are allowing people with arthritis to live healthier, more productive lives. In particular, advances in the area of disease-modifying anti-rheumatic medications (or “DMARDs”) and biologic response modifiers (or “biologics”) have radically changed health outcomes—for the better—of thousands of people living with a number of the more than 100 types of arthritis.
To ensure that all Canadians have access to the medications they need to treat their arthritis, Arthritis Consumer Experts (ACE) created the first JointHealth™ Report Card on Provincial Formulary Reimbursements for Biologic Response Modifiers in 2007. Serving as a way to keep Canadians aware of how well their province compares to the rest of Canada in its cost coverage of medications, the Report Card ranks publicly funded medication formularies based on the number of medically necessary biologic arthritis medications they list.
The Report Card is available online at jointhealth.org and updated monthly. Once a year, it is printed and distributed to JointHealth™ monthly readers and subscribers, elected officials, arthritis specialists and healthcare professionals across Canada.
A chart listing important information about the medications used to treat arthritis in Canada, called the JointHealth™ Arthritis Medications Guide.
An interview with Dr. Kam Shojania of the Arthritis Research Centre of Canada, in which he tells us about emerging medications for treating the most common forms of inflammatory and autoimmune arthritis.
Details of ACE’s campaign to raise awareness about subsequent entry biologics (SEBs) in BC, Alberta, and Ontario.
Information about exciting new research that was presented late last year in an annual conference that brings together researchers from around the world.
What’s the role of online physical activity monitors in your arthritis care?
Heard about Fitbit? Online pedometers? Exercise apps? A new study is recruiting people with any type of arthritis to find out how these physical activity trackers can be used to help people to stay active.
Have any level of experience with online tools and/or digital monitors
Live in British Columbia and Alberta
The focus group will be conducted in February and March and will last approximately 2 hours. The focus group will take place at a time and location that is most convenient for participants. You will learn about the latest in physical activity trackers in the focus group and a small honorarium will be offered to all participants.
For more information, contact Jenny Leese, Research Assistant by phone at 604-207-4006 or Toll-Free at 1-877-871-4575, or email firstname.lastname@example.org.
Anti-carbamylated protein antibodies, a recently identified autoantibody system against carbamylated proteins, can be detected in patients with rheumatoid arthritis (RA) years before they developed RA.
According to senior author of the study Dr. Leedert A. Trouw and lead author Jing Shi, Ph.D., of the department of rheumatology at Leiden (the Netherlands) University Medical Center in International Medicine News, the finding suggests “another source of antibodies which can potentially contribute to RA pathogenesis…The moment of first appearance of anti-CarP [anti-carbamylated protein] antibodies is comparable with ACPA [anti-citrullinated protein antibodies] and earlier than IgM-RF [IgM-rheumatoid factor].” ACPA and IgM-RF are both listed in the American College of Rheumatology RA criteria. Continue reading →
On October 25, Arthritis Consumer Experts (ACE) asked for your views on subsequent-entry biologics (SEBs). Health Canada defines SEBS as a “biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug.” Unlike generic medications, SEBs are not identical to their originator drugs. Since every biologic is made from living cells, even minor differences from the originator drug change the way a SEB acts in the body.
Today is the last day to complete this short survey to let us know how much you know about SEBs. Your feedback is vitally important to the work ACE conducts on behalf of the more than 456,000 Albertans living with arthritis.
Please be assured that all responses will remain anonymous and confidential. Personal information will not be collected as part of this survey.
In the annual meeting of the American College of Rheumatology, a researcher reported that a knee brace will help alleviate a patient’s osteoarthritis (OA) pains. David T. Felson, MD, of the University of Manchester in England and his colleagues found that patients with knee OA who wore a patellofemoral brace for 6 weeks experienced less pain and bone marrow lesions.
Bone marrow lesions represent regions of bone that display hyperintense signals on MRI and fibrosis, necrosis, and microfractures on histology. In an interview with MedPage Today, Felson said: “Bone marrow lesions have been shown to predict later cartilage loss and to correlate with pain and its severity, so may be a viable treatment target in OA.” Continue reading →
Every year, lupus experts and specialists volunteer their time and knowledge to help lupus patients at the Lupus Symposium. The symposium is presented by The BC Lupus Society.
The Lupus Symposium will be happening tomorrow, October 19, at St. Paul’s Hospital Lecture Theatre. Live video conferencing is available to people living in Abbotsford, Campbell River, Fort St. John, Kamloops, Kelowna, Nanaimo, Prince George, Terrace, Trail, Vernon and Victoria.